UPDATE : Friday, September 20, 2019
상단여백
Transgene parts with SillaJen, ending Pexa-Vec trial for liver cancer by Jeong Sae-im 2019-09-20 12:27
‘Galderma Korea ran background checks on unionized workers’ by Jeong Sae-im 2019-09-19 15:18
Regulator delays decision on delisting Kolon TissueGene by Jeong Sae-im 2019-09-18 14:27
Biotech startups seek IPO via ‘growth potential exception’ policy by Jeong Sae-im 2019-09-17 11:26
Chong Kun Dang wins patent suit against Novartis over immunosuppressant by Jeong Sae-im 2019-09-11 15:16
라인
Daewoong to test botulinum toxin Nabota for hair loss by Jeong Sae-im 2019-09-11 13:56
Novartis withdraws suit against Ahngook’s generic drug by Jeong Sae-im 2019-09-10 15:38
Invossa victims furious at government, Kolon for ‘doing nothing’ by Jeong Sae-im 2019-09-09 15:47
Nobel laureate Honjo anticipates best combo in immunotherapies by Jeong Sae-im 2019-09-06 16:29
Yuhan to expand biz scope to central nervous system disease by Jeong Sae-im 2019-09-06 14:56
라인
SK goes global by developing new drugs, conducting CDMO biz by Jeong Sae-im 2019-09-03 14:58
Hanmi, Daewoong among 20 innovative top-tier drugmakers in Asia Pacific by Jeong Sae-im 2019-09-02 17:33
JW Pharmaceutical’s hyperlipidemia drug Livalo safe from diabetes risk by Jeong Sae-im 2019-08-30 14:49
Change in licensing-out contract may be bad sign for Intron Biotechnology by Jeong Sae-im 2019-08-30 14:47
Antidiabetic DPP-4 inhibitors mark double-digit sales growth by Jeong Sae-im 2019-08-29 11:24
라인
Sales of new gastric acid blocker K-Cab top ₩10 billion by Jeong Sae-im 2019-08-28 13:26
Invossa victims, Kolon shareholders demand apology, compensation by Jeong Sae-im 2019-08-27 15:40
HLB to test rivoceranib+Lonsurf in colon cancer by Jeong Sae-im 2019-08-27 15:39
Regulator decides to delist Kolon TissueGene by Jeong Sae-im 2019-08-27 12:15
Pharmaceutical sector’s job growth twice of all industries’ average by Jeong Sae-im 2019-08-26 11:39
여백
여백
여백
Back to Top